A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Trial details
- Registry ID
- NCT07067463
- Phase
- Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of Orelabrutinib in Patients With Primary Progressive Multiple SclerosisNCT07067463 | Zenas BioPharma (USA), LLC | Phase 3 | Recruiting | 2030-06Estimated |
| A Study of Orelabrutinib in Patients With Secondary Progressive Multiple SclerosisNCT07299019 | Zenas BioPharma (USA), LLC | Phase 3 | Recruiting | 2030-06Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |